{"nctId":"NCT02340520","briefTitle":"Enhancement of Corticosteroid Efficacy in COPD","startDateStruct":{"date":"2014-12"},"conditions":["COPD"],"count":13,"armGroups":[{"label":"thophylline and roflumilast","type":"EXPERIMENTAL","interventionNames":["Drug: Theophylline","Drug: Roflumilast"]}],"interventions":[{"name":"Theophylline","otherNames":[]},{"name":"Roflumilast","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Established diagnosis of COPD with FEV1 \\<60% predicted\n* FEV1/FVC \\<70% and \\<+15% FEV1 response to bronchodilator.\n* Patients of both genders will be included.\n* IRB approved written informed consent will be obtained from each subject.\n\nExclusion Criteria:\n\n1. Recent (\\<1 month) exacerbation of COPD,\n2. Known hypersensitivity to beta agonists, theophylline, steroids, or roflumilast.\n3. Current or recent (\\<2 weeks) treatment with oral steroids, theophylline or other methylxanthines, or roflumlast.\n4. Diagnosis or history of asthma, uncontrolled hypertension, or congestive heart failure.\n5. History of Cardiac arrhythmia\n6. History of seizures.\n7. History of Liver disease\n8. Gastrointestinal disease, including history of peptic ulcer disease.\n9. Current infection or antibiotic treatment.\n10. History of depression or psychiatric disease.","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Bronchodilation","description":"Change in FEV1 L and FVC L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.72","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.72","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.79","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":"0.67"}]}]}]},{"type":"SECONDARY","title":"Change in HDAC2 Levels","description":"circulating Histone Deacetylase2 levels measured in blood sample","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.96","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.58","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":"0.40"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":11},"commonTop":[]}}}